Export 982 results:
Author Title Type [ Year
Filters: First Letter Of Last Name is F [Clear All Filters]
“Development of a Generic Physiologically-Based Pharmacokinetic Model for Lactation and Prediction of Maternal and Infant Exposure to Ondansetron via Breast Milk”, Clin Pharmacol Ther, vol. 5, 2022.
, “HIV Clinic-based Extended-release Naltrexone versus Treatment as Usual for People with HIV and Opioid Use Disorder: a Non-blinded, Randomized Non-inferiority Trial”, Addiction, vol. 117, no. 7, pp. 1961-1971, 2022.
, “MAS-1, A Novel Water-In-Oil Adjuvant/Delivery System, With Reduced Seasonal Influenza Vaccine Hemagglutinin Dose May Enhance Potency, Durability and Cross-Reactivity of Antibody Responses in the Elderly”, Vaccine, vol. 40, no. 10, pp. 1472-1482, 2022.
, “The Opioid Use Disorder Core Outcomes Set (OUD-COS) for Treatment Research: Findings from a Delphi Consensus Study”, Addiction, vol. 17, no. 9, pp. 2438-2447, 2022.
, “A Phase 1 Dose-Sparing, Randomized Clinical Trial of Seasonal Trivalent Inactivated Influenza Vaccine Combined With MAS-1, A Novel Water-In-Oil Adjuvant/Delivery System”, Vaccine, vol. 40, no. 9, pp. 1271-1281, 2022.
, “A Phase I Randomized, Double-blind, Single Subcutaneous Dose Escalation Study to Determine the Safety, Tolerability, and Pharmacokinetics of Rezafungin in Healthy Adult Subjects”, Clin Transl Sci, vol. 15, no. 7, pp. 1592-1598, 2022.
, “Safety and immunogenicity of a trivalent virus-like particle vaccine against western, eastern, and Venezuelan equine encephalitis viruses: a phase 1, open-label, dose-escalation, randomised clinical trial.”, Lancet Infect Dis, vol. 22, no. 8, pp. 1210-1220, 2022.
, “Short- vs Standard-Course Outpatient Antibiotic Therapy for Community-Acquired Pneumonia in Children: The SCOUT-CAP Randomized Clinical Trial”, JAMA Pediatr, vol. 176, no. 3, pp. 253-261, 2022.
, “Successful Implementation of Substance Use Screening in Rural Federally-Qualified Health Centers Identified High Rates of Unhealthy Alcohol, Cannabis, and Tobacco Use”, in The College on Problems of Drug Dependence (CPDD), Minneapolis, MN, 2022.
, “Treatment of Anal High-Grade Squamous Intraepithelial Lesions to Prevent Anal Cancer.”, N Engl J Med, vol. 386, no. 24, pp. 2273-2282, 2022.
, “Use of Population Modeling to Characterize the Pharmacokinetics of Oxcarbazepine And Its Metabolite in Children and Adolescents with Obesity”, in Annual Meeting of American Society for Clinical Pharmacology and Therapeutics (ASCPT), Virtual, 2022.
, “Antibody in Lymphocyte Supernatant (ALS) responses after oral vaccination with live Shigella sonnei vaccine candidates WRSs2 and WRSs3 and correlation with serum antibodies, ASCs, fecal IgA and shedding.”, PLoS One, vol. 16, no. 11, p. e0259361, 2021.
, “Biologic Assignment Trial of Reduced-Intensity Hematopoietic Cell Transplantation Based on Donor Availability in Patients 50-75 Years of Age With Advanced Myelodysplastic Syndrome.”, J Clin Oncol, vol. 39, no. 30, pp. 3328-3339, 2021.
, “Comparison of Methods for Alcohol and Drug Screening in Primary Care Clinics”, JAMA Network Open, vol. 4, no. 5, p. e2110721, 2021.
, “Comparison of Methods for Alcohol and Drug Screening in Primary Care Clinics”, JAMA Network Open, vol. 4, no. 5, p. e2110721, 2021.
, “The design and conduct of a randomized clinical trial comparing emergency department initiation of sublingual versus a 7-day extended-release injection formulation of buprenorphine for opioid use disorder: Project ED Innovation.”, Contemp Clin Trials, vol. 104, p. 106359, 2021.
, “Durability of mRNA-1273 vaccine-induced antibodies against SARS-CoV-2 variants.”, Science, vol. 373, no. 6561, pp. 1372-1377, 2021.
, “Durability of mRNA-1273 vaccine-induced antibodies against SARS-CoV-2 variants.”, Science, vol. 373, no. 6561, pp. 1372-1377, 2021.
, “Durability of mRNA-1273 vaccine-induced antibodies against SARS-CoV-2 variants.”, Science, vol. 373, no. 6561, pp. 1372-1377, 2021.
, “Durability of mRNA-1273 vaccine-induced antibodies against SARS-CoV-2 variants.”, Science, vol. 373, no. 6561, pp. 1372-1377, 2021.
, “Durability of mRNA-1273 vaccine-induced antibodies against SARS-CoV-2 variants.”, Science, vol. 373, no. 6561, pp. 1372-1377, 2021.
, “Human antibody responses following vaccinia immunization using protein microarrays and correlation with cell-mediated and antibody dependent cellular cytotoxicity responses.”, J Infect Dis, 2021.
, “Human Monoclonal Antibody Cocktail for the Treatment or Prophylaxis of Middle Eastern Respiratory Syndrome Coronavirus (MERS-CoV).”, J Infect Dis, 2021.
, “Immunogenicity and safety of different dose schedules and antigen doses of an MF59-adjuvanted H7N9 vaccine in healthy adults aged 65 years and older.”, Vaccine, vol. S0264-410X, no. 20, pp. 31504-31508, 2021.
, ,